The CBA works in a trifecta that includes a biobank, data platform, and bioethics team to facilitate rapid research through the sharing of data, biological materials and pathogens to researchers, industry and public health.
Dr. James Robblee is a cardiac anesthesiologist at theUniversity of Ottawa Heart Institute and an Assistant Professor in theDepartment of Anesthesiology at the University of Ottawa. With decades of clinical and academic experience, he has held leadership roles includingDivision Head of Cardiac Anesthesiology and Critical Care Medicine, and currently serves as Chair of the Board of Governors at Algonquin College. Dr. Robblee is also a Surveyor and Chair of the Physician Advisory Committee forAccreditation Canada, contributing to hospital evaluations across Canada and internationally. He holds an MBA and the ICD.D designation from the Institute of Corporate Directors.
Cleland MJ, Robblee J, Zakutney T. Monitoring Infusion pump performance through battery capacity measurement. World Congress of the World Society of Cardiothoracic Surgeons, August 2006.
Cleland MJ, Robblee J, Zakutney T. A novel approach to anesthetic delivery during cardiopulmonary bypass. World Congress of the World Society of Cardiothoracic Surgeons, August 2006.
Robblee JA, Heidemann EG. Hospital accreditation and the surgeon: the Canadian experience. Surgeon 2004 Dec;2(6):321-326, Review.
Cheng DC, Mazer CD, Martineau R, Ralph-Edwards A, Karski J, Robblee J, Finegan B, Hall RI, Latimer R, Vuylsteke A. A phase II dose-response study of hemoglobin raffiner (Hemolink) in elective coronary artery bypass surgery.
J Thorac Cardiovasc Surg 2004 Jan;127(1):79-86.Nicklin WL, McLellan T, Robblee JA. Aim for excellence: integrating accreditation standards into the continuous quality improvement framework. Health Q 2004;7(4):44-48, 2.
Dr. Raphael (Ray) Saginur is Professor Emeritus at theUniversity of Ottawa and retired Chair of the Ottawa Health Science NetworkResearch Ethics Board (OHSN-REB), where he served for over 35 years. He played a key role in establishing Canadian Association of Research Ethics Boards (CAREB) and Ontario Cancer Research Ethics Board (OCREB) and helped OHSN-REB become one ofClinical Trials Ontario’s top Boards of Record. A national leader in research ethics, Dr. Saginur has mentored numerous REB professionals and guided researchers across Ontario in conducting ethical, innovative studies.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Dr. Angela M. Crawley is an Associate Professor in theDepartment of Biochemistry, Microbiology and Immunology at the University ofOttawa and a Scientist in the Chronic Disease Program at the Ottawa HospitalResearch Institute. She also holds appointments as a PhD Scientist in theDepartment of Medicine at The Ottawa Hospital and as an Adjunct Professor inBiology at Carleton University. Her research focuses on translational immunology, with expertise in CD8 T cell function, macrophage differentiation, and immune responses in chronic liver disease and hepato cellular carcinoma. Dr.Crawley holds a PhD from the University of Guelph and completed postdoctoral training at the Ottawa Hospital Research Institute and University of Ottawa.
Odai KG., O’Dwyer C., Steenbergen R., Shaw T., Renner T., Ghorbani P., Langlois M-A., Crawley AM., Russell RS., Pezacki J., Tyrrell LD., Fullerton MD. In vitro hepatitis C virus infection and hepatic choline metabolism. Viruses, 12(1). pii: E108, 2020.
Vranjkovic A., Deonarine F., Angel JB., Cooper CL., Crawley AM. Dysfunction of bulk circulating CD8+ T-cells in chronic HCV infection is associated with liver disease severity and is unresolved after HCV cure. Frontiers Immunol., 10:1926, 2019.
Doyle MA., Lee T., Singer J., Crawley AM., Klein M., Cooper CL. Evaluation of safety and effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection. Open Forum Infectious Diseases 6(7). pii: ofz318 2019.
Ahmed F., Ibrahim A., Cooper CL., Kumar A., Crawley AM. Macrophage subsets are dysfunctional in chronic HCV infection and contribute to CD8+ T-cell impairment. Cells 2019, 8:374 - Special Issue: Hepatitis C Virus and Host Interactions, by invitation.
Doyle M-A., Mulvihill E., Galanakis C., Crawley AM., Cooper CL. Influence of Ribavirin and the Cirrhotic State on Metabolic Measures in Hepatitis C Direct Acting Antiviral Treatment Recipients. Cells 2019, 8:252 -Special Issue: Hepatitis C Virus and Host Interactions, by invitation.
Khan S., Bernier, A., Dapp D., Fortier E., Krajden M., King A., Grebely J., Sagan SM., Cooper CL., Crawley AM. 6th Canadian Symposium on HCV: Delivering a Cure for Hepatitis C Infection: What are the Remaining Gaps? Can. Liver J. 2018, Vol 1(2):94-105.
Khan S., Karges W., Cooper C., Crawley AM. Hepatitis C virus core protein reduces CD8+ T-cell proliferation, perforin production and degranulation but increases STAT5 activation. Immunol. 2018 154(1):156-65.
Steele (Leone) A.K., Carrasco-Medina L., Sodora D.L., Crawley AM. Increase in soluble IL-7 receptor levels in plasma is associated with improved therapeutic outcome to IL-7 therapy in SIV-infected ART-treated Rhesus macaques. PlosOne 2017, 12(12): e0188427.
Corsi DJ., Karges W., Thavorn K., Crawley AM., Cooper CL. Influence of female sex on hepatitis C virus infection progression and treatment outcomes. European Journal of Gastroenterology and Hepatology. 2016 28(4): 405-411.
Burke SC., Carrasco-Medina L., Karges W., Cooper CL., Crawley, AM. Generalized liver- and blood-derived CD8+ T cell impairment in response to cytokines in chronic hepatitis C virus infection. PlosOne. 2016 11(6): e0157055.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Dr. Curtis Cooper is a Professor at the University of Ottawa and an Infectious Diseases Consultant at The Ottawa Hospital. He serves as a Scientist with the Ottawa Health Research Institute and Director of The Ottawa Hospital Viral Hepatitis Program. His research focuses on viral hepatitis, HIV, and vaccine development, with an emphasis on therapeutic innovation, treatment safety, and effectiveness. Dr. Cooper also leads cohort studies related to HBV, HCV, HIV, and COVID-19.
Barter L, Cooper CL. The impact of electronic medical record system implementation on HCV screening and continuum of care: a systematic review. Ann Hepatol. 2021;24:100322.
Parmar P, Shafran S, Borgia S, Doucette K, Cooper C. Hepatitis C direct-acting antiviral outcomes in patients 75 years and older. J Gasterol Hepatol Open. 2020;5(2):253-7.
Okwor C, Oh JS, Crawley A, Cooper C, Lee S. Expression of Inhibitory Receptors on T and NK Cells Defines Immunological Phenotypes of HCV Patients with Advanced Liver Fibrosis. iScience. 2020;23(9):101513.
Lepage C, Garber G, Corrin R, Galanakis C, Leonard L, Cooper C. Telemedicine successfully engages marginalized rural hepatitis C patients in curative care. JAMMI. 2020; 5(2): 87-97.
Cooper C, Read D, Vachon ML, Conway B, Wong A, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld JJ, Lee SH, CANUHC Cohort. Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health. 2020;20(1):7
Rana U, Driedger M, Sereda P, Pan S, Ding E, Wong A, Walmsley S, Klein M, Kelly D, Loutfy M, Thomas R, Sanche S, Kroch A, Machouf N, Roy-Gagnon MH, Hogg R, Cooper CL, Canadian Observational Cohort C. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada. BMC Infect Dis. 2019;19(1):982.
Doyle MA, Lee T, Singer J, Crawley A, Klein M, Cooper C. Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection. Open Forum Infect Dis. 2019;6(7).
Khan S., Bernier, A., Dapp D., Fortier E., Krajden M., King A., Grebely J., Sagan SM., Cooper CL., Crawley AM. 6th Canadian Symposium on HCV: Delivering a Cure for Hepatitis C Infection: What are the Remaining Gaps? Can. Liver J. 2018, Vol 1(2):94-105.
Khan S., Karges W., Cooper C., Crawley AM. Hepatitis C virus core protein reduces CD8+ T-cell proliferation, perforin production and degranulation but increases STAT5 activation. Immunol. 2018 154(1):156-65.
Steele (Leone) A.K., Carrasco-Medina L., Sodora D.L., Crawley AM. Increase in soluble IL-7 receptor levels in plasma is associated with improved therapeutic outcome to IL-7 therapy in SIV-infected ART-treated Rhesus macaques. PlosOne 2017, 12(12): e0188427.
Corsi DJ., Karges W., Thavorn K., Crawley AM., Cooper CL. Influence of female sex on hepatitis C virus infection progression and treatment outcomes. European Journal of Gastroenterology and Hepatology. 2016 28(4): 405-411.
Burke SC., Carrasco-Medina L., Karges W., Cooper CL., Crawley, AM. Generalized liver- and blood-derived CD8+ T cell impairment in response to cytokines in chronic hepatitis C virus infection. PlosOne. 2016 11(6): e0157055.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Dr. Donald Vinh is a Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and Associate Professor in the Department of Medicine at McGill University. His research investigates how genetic defects in immunity predispose individuals to infectious diseases, using genomic and immunologic tools to uncover the mechanisms behind severe or atypical infections. By translating these discoveries into innovative therapies, his work bridges clinical insight and molecular science to advance understanding of human immunobiology. Dr. Vinh is recognized for his expertise in primary immunodeficiencies and translational research.
Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, Sengupta A, Brassard JP, Guerra A, Dziarmaga R, Perez A, Sun Y, Li Y, Roussel L, Langelier MJ, Ke D, Arnold C, Whelan M, Pelchat M, Langlois MA, Zhang X, Mazer BD; COVID-19 Immunity Task Force and UNCoVER Investigators. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Lancet Healthy Longev. 2022 Feb 23. doi: 10.1016/S2666-7568(22)00012-5. Epub ahead of print. PMID: 35224524.
Cheng AP, Cheng MP, Gu W, Sesing Lenz J, Hsu E, Schurr E, Bourque G, Bourgey M, Ritz J, Marty FM, Chiu CY, Vinh DC, De Vlaminck I. Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med (N Y). 2021 Apr 9;2(4):411-422.e5. doi: 10.1016/j.medj.2021.01.001. Epub 2021 Jan 16. PMID: 33521749.
Golizeh M, Winter K, Roussel L, Landekic M, Langelier M, Loo VG, Ndao M, Vinh DC. Fecal host biomarkers predicting severity of Clostridioides difficile infection. JCI Insight. 2021 Jan 11;6(1):e142976. doi: 10.1172/jci.insight.142976. PMID: 33232301.
Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585. doi: 10.1126/science.abd4585. Epub 2020 Sep 24. PMID: 32972996.
Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, Foulkes WD, Veillette A, Vinh DC. Loss of human ICOSL results in combined immunodeficiency. J Exp Med. 2018 Dec 3;215(12):3151-3164. doi: 10.1084/jem.20180668. PMID: 30498080.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
